Free Trial

Maury Raycroft Analyst Performance

Analyst at Jefferies Financial Group

Maury Raycroft is a stock analyst at Jefferies Financial Group in the medical sector, covering 20 publicly traded companies. Over the past year, Maury Raycroft has issued 8 stock ratings, including buy and hold recommendations. While full access to Maury Raycroft's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Maury Raycroft's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
30 Last 8 Years
Buy Recommendations
68.97% 20 Buy Ratings
Companies Covered
20 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy69.0%20 ratings
Hold31.0%9 ratings
Sell0.0%0 ratings

Out of 29 total stock ratings issued by Maury Raycroft at Jefferies Financial Group, the majority (69.0%) have been Buy recommendations, followed by 31.0% Hold.

Exchange Coverage

ExchangePercentageCount
NASDAQ
95.0% of companies on NASDAQ
19 companies
NYSE
5.0% of companies on NYSE
1 company

Maury Raycroft, an analyst at Jefferies Financial Group, currently covers 20 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
20 companies
100.0%

Maury Raycroft of Jefferies Financial Group specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
9 companies
45.0%
PHARMACEUTICAL PREPARATIONS
6 companies
30.0%
MED - DRUGS
2 companies
10.0%
MED PRODUCTS
1 company
5.0%
BIOTECHNOLOGY
1 company
5.0%
LARGE CAP PHARMA
1 company
5.0%

Maury Raycroft's Ratings History at Jefferies Financial Group

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
9/22/2025Initiated Coverage$12.97$15.00Buy
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
9/10/2025Set Price Target$27.31$35.00
Valneva SE Sponsored ADR stock logo
VALN
Valneva
8/25/2025Set Price Target$9.08$14.00Buy
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
7/7/2025Boost Price Target$323.82$384.00Buy
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
6/24/2025Initiated Coverage$3.16$3.50Hold
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
3/11/2025Lower Price Target$6.86$53.00Buy
Chimerix, Inc. stock logo
CMRX
Chimerix
3/5/2025Reiterated Rating$8.46$8.50Hold
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
2/10/2025Boost Price Target$3.90$8.00Buy